Cramer: Apple Is Th...
Health Care: Drugs
Elan Corp PLC (ELN: NYSE)
$13.39 -0.57 | -4.08%
06/01/12 - 04:03 PM ET
Company Income Statement
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Sales | 1.25B | 1.17B | 1.11B | 1.00B |
| Cost of Sales | 599.10M | 514.90M | 480.40M | 420.70M |
| Gross Operating Profit | 646.90M | 654.80M | 632.60M | 579.50M |
| Selling, General, and Administrative Expenses | 228.70M | 461.00M | 268.20M | 292.70M |
| Research & Development | 232.50M | 258.70M | 293.60M | 323.40M |
| Operating Income before D & A (EBITDA) | 185.70M | -64.90M | 70.80M | -36.60M |
| Depreciation & Amortization | 40.60M | 68.40M | 80.30M | 72.70M |
| Interest Income | 0.00 | 0.00 | 0.00 | 11.20M |
| Other Income - Net | 568.90M | -29.20M | 98.30M | -56.00M |
| Special Income / Charges | 0.00 | -16.70M | -46.00M | 0.00 |
| Total Income Before Interest Expenses (EBIT) | 714.00M | -204.80M | 8.10M | -154.10M |
| Interest Expense | 105.90M | 117.80M | 137.90M | 143.20M |
| Pre-Tax Income | 608.10M | -322.60M | -129.80M | -297.30M |
| Income Taxes | 47.60M | 2.10M | 46.40M | -226.30M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | 560.50M | -324.70M | -176.20M | -71.00M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | 560.50M | -324.70M | -176.20M | -71.00M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | 560.50M | -324.70M | -176.20M | -71.00M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
560.50M | -282.40M | -95.50M | -71.00M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | 560.50M | -324.70M | -176.20M | -71.00M |
| Basic EPS from Continuing Ops. | 0.95 | -0.56 | -0.35 | -0.15 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | 0.95 | -0.56 | -0.35 | -0.15 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | 0.95 | -0.56 | -0.35 | -0.15 |
| Basic Normalized Net Income/Share | 0.95 | -0.49 | -0.19 | -0.15 |
| EPS fr Continuing Ops. | 0.94 | -0.56 | -0.35 | -0.15 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | 0.94 | -0.56 | -0.35 | -0.15 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | 0.94 | -0.56 | -0.35 | -0.15 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
0.94 | -0.49 | -0.19 | -0.15 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with ELN
- Portfolio NameUser Type
- Contributor22 Biopharma Stocks With Br...
- ProGeorge Soros
- UserGFNN Stockdiagnostics 13
- ContributorBreakout Stocks Of The Week...
- UserGFNN Stockdiagnostics
- ContributorRelative Strength Trades fo...
- ContributorStocks At New 52-Week Highs...
- ProRobert Bruce
- ContributorTechnical Setups for the We...
- Contributor10 Health Care Stocks With ...
Latest ELN Headlines from TheStreet
- 22 Biopharma Stocks With Breakout Potential in 2012 05.22.12 | 08:05 am
- A Health Care Fortnight for the Record Books 05.14.12 | 07:05 am
- On Nowruz, Reviewing Drug Stock Picks 03.26.12 | 07:03 am
- Elan's Alzheimer's-Fueled Run Means Investors Are Forgetting the Past 03.19.12 | 07:03 am
- The Case for Shorting Elan Into Upcoming Alzheimer's Trial Results 02.21.12 | 07:02 am
- Medivation Shrugs Off Alzheimer's Setback as Investors Eye New Prostate Cancer Data 01.17.12 | 09:01 am
- 7 Relative Strength Stocks for 2012 12.29.11 | 05:12 pm
- 7 Stocks Hitting New 52-Week Highs 12.21.11 | 01:12 pm
- Your Vote Counts: Who is the Worst Biotech CEO of 2011? 12.01.11 | 10:12 am
- Good Biotech Stocks for a Bear Market 08.09.11 | 08:08 am
Press Releases for ELN
- Elan To Present At Jefferies 2012 Global Healthcare Conference - Business Wire 05.28.12 | 08:05 am
- New Analysis Of Risk Stratification For TYSABRI® Published In New England Journal Of Medicine - Business Wire 05.17.12 | 03:05 pm
- Elan Reports First Quarter 2012 Financial Results - Business Wire 04.26.12 | 02:04 am
- Elan Announces Webcast Of First Quarter 2012 Financial Results - Business Wire 04.12.12 | 04:04 pm
- Elan Raises $381 Million In Sale Of 76% Of Alkermes Holding - Business Wire 03.13.12 | 12:03 pm
- Elan Chairman Provides Update On CEO Succession - Business Wire 03.01.12 | 02:03 am
- Elan Reports Fourth Quarter And Full-Year 2011 Financial Results - Business Wire 02.08.12 | 02:02 am
- Elan To Present At The Leerink Swann 2012 Global Healthcare Conference - Business Wire 02.01.12 | 04:02 pm
- ASCEND Study To Evaluate The Effectiveness Of TYSABRI® (natalizumab) As A Treatment For Secondary-Progressive Multiple Sclerosis - Business Wire 01.26.12 | 08:01 am
- FDA Updates TYSABRI® (natalizumab) Label To Include Anti-JC Virus Antibody Status As A PML Risk Factor - Business Wire 01.20.12 | 04:01 pm
Partner Headlines for ELN
- Healthcare Biz Recap: Express Scripts New Driver, Elan Pops - Wall St. Cheat Sheet 05.27.12 | 12:05 pm
- Billionaire Soros' Q1 High Conviction Buys In 2 Growth Stocks, Other Buys And Sells - Seeking Alpha 05.18.12 | 08:05 pm
- Revenues Climb at Acorda - Analyst Blog - Zacks 05.04.12 | 06:05 pm
- Elan Misses 1Q EPS, Revenues Rise - Analyst Blog - Zacks 05.01.12 | 09:05 am
- Elan Sells 76% Stake in Alkermes - Analyst Blog - Zacks 03.16.12 | 05:03 pm
- Tuesday's Bio Pharma Watch List - Seeking Alpha 02.28.12 | 08:02 am
- Zacks Sell List Highlights: Expedia, NII Holdings, Elan and Gentex - Press Releases - Zacks 02.17.12 | 09:02 am
- NII HLDGS-CL B (NIHD) - Profit Tracks - Zacks 02.17.12 | 01:02 am
- The Zacks Analyst Blog Highlights: Alkermes plc, Elan, Johnson & Johnson, Amylin Pharmaceuticals and Eli Lilly & Company - Press Releases - Zacks 02.06.12 | 09:02 am
- The Zacks Analyst Blog Highlights: Pfizer, Biogen Idec, Elan, Novartis and Roche - Press Releases - Zacks 02.01.12 | 09:02 am
